---
title: "强生宣布 2.1% 的股息，并报告了 Tremfya 的数据"
description: "强生（Johnson & Johnson，JNJ）宣布股息收益率为 2.1%，股息金额为 1.30 美元，作为 2024 年 2 月 24 日的除息股票名单的一部分。强生还报告了 Tremfya（guselkumab）的长期数据，显示在三年期间，溃疡性结肠炎患者的临床和内镜缓解持续存在"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276519560.md"
published_at: "2026-02-21T20:03:10.000Z"
---

# 强生宣布 2.1% 的股息，并报告了 Tremfya 的数据

> 强生（Johnson & Johnson，JNJ）宣布股息收益率为 2.1%，股息金额为 1.30 美元，作为 2024 年 2 月 24 日的除息股票名单的一部分。强生还报告了 Tremfya（guselkumab）的长期数据，显示在三年期间，溃疡性结肠炎患者的临床和内镜缓解持续存在

-   强生 (Johnson & Johnson, JNJ) 宣布股息收益率为 2.1%，股息金额为 1.30 美元，作为 2 月 24 日的除息股票名单的一部分。
-   强生报告了 Tremfya (guselkumab) 的长期数据，显示在三年期间，溃疡性结肠炎患者的临床和内镜缓解持续存在。

### Related Stocks

- [IHE.US - 美国制药 ETF - iShares](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [XLV.US - 医疗业 ETF - SPDR](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [IXJ.US - 标普全球医疗股指数 ETF - iShares](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [JNJ.US - 强生](https://longbridge.com/zh-CN/quote/JNJ.US.md)
- [VHT.US - 医疗业 ETF - Vanguard](https://longbridge.com/zh-CN/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 5,056 Shares in Johnson & Johnson $JNJ Acquired by Uniting Wealth Partners LLC | Uniting Wealth Partners LLC acquired 5,056 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at approximately $938,0 | [Link](https://longbridge.com/zh-CN/news/276006840.md) |
| TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years \| JNJ Stock News | Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical a | [Link](https://longbridge.com/zh-CN/news/276513760.md) |
| FDA untitled letter lambastes claims in ad for J&J’s Tremfya | The FDA has issued an untitled letter to Johnson & Johnson regarding misleading claims in advertisements for Tremfya, a  | [Link](https://longbridge.com/zh-CN/news/276359346.md) |
| BUZZ-Johnson & Johnson rises on planned $1 billion investment in Pennslyvania | Shares of Johnson & Johnson (JNJ) rose 0.3% to $244.40 following the announcement of a planned investment exceeding $1 b | [Link](https://longbridge.com/zh-CN/news/276261089.md) |
| Johnson & Johnson Announces New Long-Term Data from the Quasar Long-Term Extension Study | Johnson & Johnson announced new long-term data from the QUASAR study, showing that TREMFYA® (guselkumab) sustained clini | [Link](https://longbridge.com/zh-CN/news/276518257.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。